Search results
Added:
7 months ago
Source:
HFSA 2025 Scientific Programme
HSFA Annual Scientific Meeting 2025 has released its late-breaking clinical research sessions which are to be presented in September 2025.The meeting is set to take place from the 26th to 29th September 2025 at Minneapolis Convention Center in Minnesota, US.Access the full programme here.Late Breaking Clinical Research 1: Devices and CardiomyopathiesSunday 28th September, 09:00am – 10:30am (CDT…
View more
Added:
5 months ago
Source:
Radcliffe Cardiology
Differentiating cardiac amyloidosis (CA) from its phenotypic mimics remains a clinical challenge. A new study published in the European Heart Journal details the development and validation of a novel artificial intelligence (AI) model that can accurately screen for CA using only a single apical four-chamber echocardiogram video clip.¹This retrospective, multisite, multiethnic study first trained…
View more
Added:
7 months ago
Source:
Radcliffe Cardiology
The ODYSSEY-HCM trial, evaluating the cardiac myosin inhibitor mavacamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (HCM), did not meet its dual primary endpoints for improving functional capacity or patient-reported symptoms.¹ The findings were presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously published in the New England…
View more
Added:
4 months ago
Source:
Radcliffe Cardiology
A new post hoc analysis of the SUMMIT trial suggests the HFpEF-ABA score is a more effective and inclusive enrichment tool than natriuretic peptide (NP) levels for clinical trials in patients with obesity-related heart failure with preserved ejection fraction (HFpEF).¹ The findings indicate the score, which is based on age, body mass index (BMI), and history of atrial fibrillation (AF), can…
View more
Added:
5 months ago
Source:
Radcliffe Cardiology
New analyses from the ATTRibute-CM trial show that the transthyretin (TTR) stabiliser acoramidis provides consistent clinical benefits in patients with both wild-type (ATTRwt-CM) and variant (ATTRv-CM) transthyretin amyloid cardiomyopathy.1 The findings include data from the main 30-month trial and its ongoing 42-month open-label extension (OLE).Acoramidis is an orally administered, small…
View more
Added:
1 year ago
Source:
ESC Congress
The European Society of Cardiology has revealed 12 Hot-Line trial sessions to be presented at the end of August.ESC Congress 2024 will be held from the 30thAugust to the 2nd September at the ExCel Center in London. View the full programme here.Don't miss our video collection covering late-breaking data from ESC Congress 2024, including a preview of the most anticipated trials in View from the…
View more
Added:
2 years ago
Source:
Radcliffe Cardiology
AUTHOR: Greg GuilloryTwo late-breaking clinical trials addressing cardiovascular outcomes in patients with diabetes were presented this week at the American College of Cardiology meeting in Atlanta, USA. One of these trials looked at the effects of the hyperactivation of the polyol pathway on diabetic cardiomyopathy (DbCM) and the other the effects of chelation therapy in patients with diabetes…
View more